Thanks for Signing Up!

One more step to take -

1. Reply back to this email to ensure that we don't end up in SPAM! ( We don't belong there anyways!) or Place us on your safe sender list by adding us to your contacts. Select the add/save to address book function in your email browser and follow the given instructions. Or Reply back to our email!

Our sender name is Penny Stock Titans, and our email address is info@pennystocktitans.com

While you're waiting for our next huge pick, take a look at our LONG-TERM PICK OF THE YEAR!




ITNS IS OUR MONSTER PICK OF THE YEAR!


From The Mind Behind
Zicam®!





This Tiny Company's Medical Breakthrough May Soon Be In Every Hospital And Doctor's Office Around The World – Ensuring That You May NEVER Have To Be Nauseas Again!

Getting In Now Is Like Getting In On Aspirin BEFORE It Changed The World!

Undiscovered Itonis Inc. (ITNS) may have just revealed one of the biggest medical breakthroughs this Century! Taking a page out of ZICAM's® book, their unique delivery method is the secret... and early investors could walk away with 1,150% gains!

That means every $2K invested could be worth $23,000!! Every $5K invested could be worth
 a WHOPPING $57,500!!


Dear Fellow Investor:

The company you're going to learn about today is on the verge of what could be one of the most amazing products to hit the medical world in the past 10 years.

It's not the fact that they've discovered an over-the-counter solution to nausea...

No, it's the unique and virtually INSTANT, delivery system they've incorporated to administer this breakthrough medicine that may soon put Emesyl® in every pharmacy, in every hospital and every doctor's office in the country!

But what's more important for investors like you – is the fact that this tiny stock could be one of the biggest winners on Wall Street...

And not just this year – but of all time!

 
FEATURED STOCK
ITNS
STOCK QUOTE: $--   --
 
Market Value: $10,513,265 a/o Aug 29, 2014

Shares Outstanding: 930,377,519 a/o Aug 31, 2014

Preferred Shares: 5,000,000

Float: 569,631,717 a/o Aug 31, 2014

Authorized Shares: 1,000,000,000 a/o Aug 31, 2014

Par Value: 0.001

Shareholders of Record: 662 a/o Aug 31, 2014

Number of Beneficial Shareholders: Approx 1

Total number of Shareholders: 662

www.itonisholdings.com


Why? Because this stock is priced so low right now – that even just a $200 investment could return your THOUSANDS within the next few months.

Soon, very soon, Emesyl® could be stocked on the shelves of your local drug store or the medicine aisle of your favorite grocery store...

Especially if the man that brought us one of the biggest over-the-counter cold remedies to ever hit the free market in Zicam® has anything to say about it!

And you can bet the moment you see this product being sold – the REAL profits to be had will already be made! That's why your timing on this one is so important...


BREAKTHROUGH: How Dr. Hensley's Newest Innovation Could Ensure The World Never Gets Nauseas Again!

When Dr. Charles Hensley first formulated Zicam® - you can be sure he didn't envision how big his creation would become...

But $25 Million per year in revenue proved that not only was he on the right path – but that path was paved with gold!

It's been a few years since Dr. Hensley has come out with a new product – but ITNS knew that by signing this innovator on to the company – it would only be a matter of time till something BIG was revealed...

And Emesyl® could be HUGE! And it could be about to put one of the biggest motion sickness companies on notice!

Dr. Hensley and ITNS have just revealed their nasal and/or sublingual spray for the alleviation of mild to moderate nausea caused by ailments such as
  • motion sickness
  • dizziness
  • migraines
  • gastroenteritis
  • food poisoning
And do so without many of the common side effects associated with current OTC and prescription treatments, such as extreme drowsiness or tolerance build up.

This is HUGE...

Dr. Hensley has gone on to comment, "There have been relatively few innovations within this product category over the past few years and we believe the market is ripe for a new type of nausea preparation that is available over-the-counter. We believe this new preparation will be both safe and effective for a wide range of nausea related conditions."

Even bigger...

Emesyl® may even be effective to combat nausea in patients undergoing chemotherapy treatments!


While the actual size of the market for nausea related drugs and preparations is difficult to estimate, it's been suggested the market may be over half a billion dollars annually. If this is the case, Emesyl® could grab a huge chunk of that market – as their delivery system is virtually instantaneous – and with Dr. Hensely behind it, gives it automatic credibility!



That makes the profit potential for ITNS almost LIMITLESS!!

Is Zicam's® Parent Company Willing To Pay
 $24 Million For ITNS?

$24 Million may not sound like a lot of cheddar in the world of Blue Chip stocks...

But in the world of Small Caps - $24 Million is MORE than worth it's weight in gold – as that amount could send the tiny stock prices soaring! You're probably asking yourself where we're getting that $24 Million amount from...

Well, back in 2012 – Zicam's® parent company, Matrixx Initiatives made a play for one of their competitors, ProPhase Labs – the parent company of popular cold remedy, Cold-EEZE...

The deal would have been worth $24 Million to the shareholders.

In the end, ProPhase Labs declined Matrixx Initiatives offer – and while that may have been a bad thing for ProPhase shareholders – it could be a very GOOD thing for shareholders of ITNS.

You see, as we said a few moments ago – in the stock world, $24 Million doesn't seem like a lot of money - $24 Million could be the daily dollar volume of some of the Big Boys...

But to a stock like ITNS – and influx of cash in that amount would be HUGE...

1,150% profits kind of huge!

Right now, if you take ITNS's current market cap – infuse that $24 Million into it – it's be 11 ½ times BIGGER than it is now!

And seeing as Dr. Hensley has STRONG ties to Matrixx – this deal may be a LOT easier to make than it was with ProPhase.


Not only that...

This would be a BRAND new market for the makers of Zicam®!

Meaning a whole new revenue stream from a market that could soon be dominated by Emesyl®!

That is... if ITNS decides to sell – as the potential for even MORE money may lie in wait in the MORE than $500 Million over-the-counter anti-nausea market.

This Penny Stock Could Make You A FORTUNE...
 If You Act Now!

ITNS's Emeysl® may be about to bust the more-than-$500 Billion anti-nausea market wide open!

The stage is set for this company to be of the biggest small caps of the year...

With ties to one of the biggest over-the-counter home remedy companies – ITNS could be on the verge of a breakout – and investors who act now, could be eying a 1,150% return!

What this could mean for you, is a financial windfall unlike any that you've ever seen before.

Don't let this company pass you by...

This is no "fly-by-night" operation, Emesyl® is a medical wonder that could have you profiting big now, and even bigger later.

Happy Investing,
PennyStockTitans.com


PS. We're telling you now, ITNS has all the right pieces in play to become one of the most profitable stocks we've seen in a long time. With power players like Dr. Hensley behind this revolutionary breakthrough, it could be just a matter of time before shares start soaring north!!

PPS. Emesyl® could change the way the world takes it's anti-nausea medication. By implementing an almost instantaneous delivery system – ITNS may have set things in motion to capture a HUGE chunk of their $500 Billon plus industry. Start your own research on ITNS today!




GENERAL NOTICE AND DISCLAIMER - PLEASE READ CAREFULLY We are engaged in the business of marketing and advertising companies for monetary compensation. All content in our releases is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a solicitation of the purchase or sale of any securities. Pennystocktitans.com sponsored advertisements do not purport to provide an analysis of any company's financial position, operations or prospects and this is not to be construed as a recommendation by Pennystocktitans.com or an offer or solicitation to buy or sell any securities. None of the owners of Pennystocktitans.com, or any of its members, officers, directors, contractors or employees is a licensed broker-dealer, account representative, market maker, investment banker, investment advisor, analyst or underwriter. Investing in securities, including the securities of those companies profiled or discussed on this website is for individuals tolerant of high risks. Viewers should always consult with a licensed securities professional before purchasing or selling any securities of companies profiled or discussed in our releases. It is possible that a viewer's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Pennystocktitans.com makes no recommendation that the securities of the companies profiled or discussed in our releases or on our website should be purchased, sold or held by investors. Pennystocktitans.com makes no representations, warranties or guarantees as to the accuracy or completeness of the information provided or discussed. Viewers should use the information provided by us regarding the profiled companies as a starting point for additional independent research on the companies profiled or discussed in order to allow the viewer to form his or her own opinion regarding investing in the securities of such companies. Factual statements, or the similar, made by the profiled companies are made as of the date stated and are subject to change without notice and Pennystocktitans.com has no obligation to update any of the information provided, nor is it responsible for errors and omissions. From time to time certain content in our releases or website is written and published by our employees or third parties. In addition to information about our profiled companies, from time to time, our releases and website will contain the symbols of companies and/or news feeds about companies that are not being profiled by us but are merely illustrative of certain activity in the micro cap or penny stock market that we are highlighting. Viewers are advised that all analysis reports and news feeds are issued solely for informational purposes. Any opinions expressed are subject to change without notice. It is also possible that one or more of the companies discussed or profiled in our releases or on our website may not have approved certain or any statements within the release or website. Pennystocktitans.com encourages viewers to supplement the information obtained from any release or our website with independent research and other professional advice. By accessing, viewing, or using our website or communications originating from our website or any release therein, you agree that Pennystocktitans.com, its owners, officers, directors, contractors and employees, are not responsible for any content, associated links, resources, or services associated with a third party website. You further agree that Pennystocktitans.com, its owners, officers, directors, contractors and employees shall not be liable for any loss or damage of any sort associated with your use of third party content. Links and access to these sites are provided for your convenience only. Pennystocktitans.com uses third parties to disseminate information to subscribers. Although we take precautions to prevent others from obtaining our subscriber list, there is a risk that our subscriber list, through no wrong doing on our part, could end up in the hands of an unauthorized party and that subscribers will receive communications from unauthorized third parties. You agree to hold Pennystocktitans.com, its operators, owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur arising out of the use of our website or the information in our press releases, profiles and opinions. You agree that use of our website is at your sole risk. Pennystocktitans.com disclaims all warranties of any kind, express or implied. We encourage viewers to invest carefully and read the investor issuer information available at the web sites of the SEC. The SEC has launched an investor-focused website to help you invest wisely and avoid fraud at www.investor.gov and filings made by public companies can be viewed at www.sec.gov and/or then FINRA at: www.finra.org . In addition, FINRA has published information at its website on how to invest carefully at www.finra.org/investors/index.htm. Questions regarding any information contained in this website may be sent to info@pennystocktitans.com To review our complete disclaimer and additional information, please visit www.pennystocktitans.com COMPANY SPECIFIC DISCLAIMER Some of the content in this release may contain forward-looking information within the meaning of Section 27 A of the Securities Act of 1933 and Section 21 E of the Securities Exchange Act of 1934 including statements regarding expected continual growth of the profiled companies and the value of their securities. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, it is hereby noted that statements contained herein that look forward in time which include everything other than historical information, involve risk and uncertainties that may affect the company's actual results of operation. The company's actual performance could greatly differ from those described in any forward looking statements or announcements mentioned in our releases. A company's past performance does not guarantee future results. Further specific financial information, filings and disclosures as well as general investor information about the profiled companies, advice to investors and other investor resources are available at the Securities and Exchange Commission (“SEC”) website www.sec.gov and the Financial Industry Regulatory Authority (“FINRA”) website at www.finra.org. The content in this release is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. This release may provide hyperlinks to third party websites or access to third party content. Pennystocktitans.com, its owners, officers, directors, contractors and employees are not responsible for errors and omissions nor does Pennystocktitans.com control, endorse, or guarantee any content found in such sites. Pennystocktitans.com is affiliated with Think Group Media LLC whom expects to be compensated a total amount of 90,000,000 Shares of restricted stock for a one year marketing agreement with Itonis (OTC:ITNS). which services include the issuance of this release and other opinions that we release concerning of Itonis (OTC:ITNS) .Pennystocktitans.com has not investigated the background of Itonis (OTC:ITNS). Pennystocktitans.com has received this amount as a production budget for advertising efforts and will retain amounts over and above the cost of production, copywriting services, mailing and other distribution expenses as a fee for our services. As such, our opinion is neither unbiased nor independent, and you should consider that when evaluating our statements about Itonis (OTC:ITNS).